Lumida
/OCUL
⌘K
Ocular Therapeutix Inc

Ocular Therapeutix Inc

OCUL
$10.49USD-1.22%-0.13 today

MARKET CAP

2.3B

P/E (TTM)

FWD P/E

DAY RANGE

$10 – $11

52W RANGE

$6
$16

AI Summary

Stalk
Buy NowMedium

OCUL's active lockout rally underpins a medium-term bullish bias, with price pulling back into the rising EMAs within a key support zone. Short-interest squeeze dynamics support forced participation, and the long-term uptrend remains intact above the 200-SMA. The current pullback offers a favorable entry point for continuation participation, while failure to hold EMAs or volume follow-through would warrant caution.

  • Expect AXPAXLI NDA submission in Q4 2026, leveraging positive SOL-1 Week 52 data
  • Cash runway of $598.6M extends funding into 2028 for trials and launch
  • Q2 net loss of $78.8M ($0.35/share) on flat $13.5M revenue
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$43.5M$51.5M$58.4M$63.7M$52.0M
YoY %+150.1%+18.3%+13.5%+9.0%-18.5%
P / Sales13.2x4.5x7.0x21.2x43.8x
EV / Sales12.1x4.7x6.4x17.3x32.5x
Gross Profit, Adj.$39.1M$47.0M$53.2M$58.1M$45.4M
YoY %+155.3%+20.0%+13.2%+9.3%-21.9%
Margin %89.9%91.2%91.0%91.2%87.3%
EV / Gross Profit13.4x5.2x7.1x19.0x37.2x
EBITDA, Adj.$-75.6M$-76.5M$-79.4M$-168.0M$-265.7M
YoY %-25.9%-1.2%-3.7%-111.6%-58.2%
Margin %-173.7%-148.6%-135.9%-263.6%-511.4%
EV / EBITDA-6.9x-3.2x-4.7x-6.6x-6.4x
EBIT$-78.0M$-78.7M$-82.4M$-171.8M$-270.0M
YoY %-24.2%-0.8%-4.7%-108.5%-57.2%
Margin %-179.3%-152.7%-141.0%-269.6%-519.8%
EV / EBIT-6.7x-3.1x-4.6x-6.4x-6.3x
Net Income$-6.6M$-71.0M$-80.7M$-193.5M$-265.9M
YoY %+95.8%-984.1%-13.7%-139.7%-37.4%
Net Margin-15.1%-138.0%-138.1%-303.7%-511.9%
EPS (GAAP)-$0.98-$0.97-$1.02-$1.22-$1.42
YoY %+61.7%+1.0%-5.2%-19.6%-16.4%